| In response to difficulties prescribing anti-tumour drugs after their inclusion in health insurance, and to issues arising from DRG [Diagnosis-Related Group] and disease-based payment policies that lead severely ill patients to undergo staged surgeries or be discharged and readmitted, will raise these concerns with regulators in coordination with the media. | がん
> がん：ほとんどの種類 | 規制上のパートナーシップ
> 規制機関との連携 | 100,000 | National | Sometimes | 114998326269 |
| We submit surveys/proposals to CFDA [China Food and Drug Administration] and CDE [Center for Drug Evaluation]. | 呼吸器
> 肺高血圧症 | 規制上のパートナーシップ
> 規制機関との連携 | 10,000 | National | Regularly | 115007302730 |
| With respect to newly marketed medicinal products, in our capacity as the initiating body of a patient assistance programme, we gather patient perspectives and, where a therapy demonstrably meets patients' clinical needs and no clinically equivalent alternative is available in China, we advocate for its market authorisation in the country — as we have done for medicines such as secukinumab [biologic medication used to treat autoimmune conditions like plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis] and Nefecon [corticosteroid budesonide used to treat primary Immunoglobulin A nephropathy]. | 全般的な健康状態
> 公衆衛生 | 規制上のパートナーシップ
> マーケティング承認申請への貢献 | 100,000 | National | Sometimes | 115023378250 |
| I have received an invitation from the CDE [药品审评中心 – Center for Drug Evaluation] to participate in a closed-door meeting. | がん
> がん：血液 | 規制上のパートナーシップ
> 政策立案者・規制当局との会議への出席・ファシリテーション | 100,000 | National | Rarely | 115007439380 |
| Roundtable discussions are primarily convened by invitation from the NMPA [National Medical Products Administration]. | がん
> がん：血液 | 規制上のパートナーシップ
> 政策立案者・規制当局との会議への出席・ファシリテーション | 100,000 | National | Rarely | 115008256034 |
| Communicating and raising concerns with the NHSA [国家医疗保障局 – National Healthcare Security Administration/China]. | レア
> ファブリー病 | 規制上のパートナーシップ
> 政策立案者・規制当局との会議への出席・ファシリテーション | 1,000 | National | Regularly | 115013642356 |
| We use questionnaires to gather insights into the patient population and share the resulting survey data at meetings with policymakers. | がん
> がん：ほとんどの種類 | 規制上のパートナーシップ
> 政策立案者・規制当局との会議への出席・ファシリテーション | 100,000 | National | Sometimes | 115033327817 |
| Participating in policy consultations and attending regulatory authority-led seminars that incorporate patient perspectives. | レア
> 希少疾患：ほとんどの種類 | 規制上のパートナーシップ
> 政策立案者・規制当局との会議への出席・ファシリテーション | 5,000 | National | Rarely | 115063429838 |
| Submitting advocacy letters to regulatory authorities. | レア
> 希少疾患：ほとんどの種類 | 政策と法律への影響
> 医療政策と法律に影響を与える | 1,000 | National | Regularly | 115029711188 |
| Policy advocacy and healthcare access support constitute the core areas of business. | 肝臓
> 肝炎 | 政策と法律への影響
> 医療政策と法律に影響を与える | 100,000 | National | Regularly | 115050575369 |
| Proposals submitted to the Lianghui [两会 – the annual plenary sessions of China's National People's Congress and the Chinese People's Political Consultative Conference]. | 全般的な健康状態
> 公衆衛生 | 政策と法律への影響
> 公聴会やパブリックコンサルテーションに参加する | 100,000 | National | Regularly | 115023383007 |
| Participating in policy consultations and attending regulatory authority-led seminars that incorporate patient perspectives. | レア
> 希少疾患：ほとんどの種類 | 政策と法律への影響
> 公聴会やパブリックコンサルテーションに参加する | 5,000 | National | Rarely | 115063429838 |
| We conduct research — covering areas such as pricing and related matters — and relay the findings to the relevant regulatory authorities. | がん
> がん：ほとんどの種類 | 価格設定と手頃な価格の擁護
> 公正な医薬品価格の実現を推進する | 100,000 | National | Sometimes | 115030437530 |
| Patient-facing media advocacy content relating to healthcare insurance coverage. | がん
> がん：ほとんどの種類 | 価格設定と手頃な価格の擁護
> 公正な医薬品価格の実現を推進する | 100,000 | National | Sometimes | 115032740364 |
| We raise our voice on the issue of drug pricing. | 内分泌
> 糖尿病：2型 | 価格設定と手頃な価格の擁護
> 公正な医薬品価格の実現を推進する | 10,000 | Regional | Rarely | 115051912364 |
| In our capacity as the initiating organization of a Patient Assistance Program (PAP) for newly approved medicines, we gather and represent patient perspectives. Where a genuine unmet clinical need exists and no clinically viable alternative is available in China, we advocate for the regulatory approval and market authorization of therapies such as secukinumab [biologic medication used to treat autoimmune conditions like plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis] and Nefecon [corticosteroid budesonide used to treat primary Immunoglobulin A nephropathy], while providing evidence on the financial burden borne by patients. | 全般的な健康状態
> 公衆衛生 | 価格設定と手頃な価格の擁護
> 低所得者や脆弱な立場にある人々のコスト面での障壁に対処する | 100,000 | National | Sometimes | 115023378250 |
| In response to difficulties prescribing anti-tumour drugs after their inclusion in the NRDL [ 国家医保药品目录 - China's National Reimbursement Drug List], and to issues arising from DRG [Diagnosis-Related Group] and disease-based payment policies that lead severely ill patients to undergo staged surgeries or be discharged and readmitted, we will raise these concerns with regulators in coordination with the media. | がん
> がん：ほとんどの種類 | 価格設定と手頃な価格の擁護
> 薬価の追跡・監視/医薬品不足 | 100,000 | National | Sometimes | 114998326269 |
| We conduct research — covering areas such as pricing and related matters — and relay the findings to the relevant regulatory authorities. | がん
> がん：ほとんどの種類 | 価格設定と手頃な価格の擁護
> 薬価の追跡・監視/医薬品不足 | 100,000 | National | Sometimes | 115030437530 |
| We advocate for the inclusion of medications within the national medical insurance formulary, as well as for greater ease of access to treatments. | 神経学的
> 多発性硬化症 | 価格設定と手頃な価格の擁護
> 製品の償還リスト/国家医薬品集への収載推進 | 10,000 | National | Sometimes | 115000464773 |
| We advocate for the inclusion of medications within the national medical insurance formulary, as well as for greater ease of access to treatments. | 神経学的
> 多発性硬化症 | 価格設定と手頃な価格の擁護
> 製品の償還リスト/国家医薬品集への収載推進 | 10,000 | National | Sometimes | 115000464773 |
| I will advocate on issues relating to pharmaceutical pricing and the inclusion of pharmaceutical products and medical devices in the national medical insurance (NMI) reimbursement market. | 内分泌
> 糖尿病：2型 | 価格設定と手頃な価格の擁護
> 製品の償還リスト/国家医薬品集への収載推進 | 10,000 | Regional | Rarely | 115051912364 |
| Patient-facing media advocacy content relating to healthcare insurance coverage [in China]. | がん
> がん：ほとんどの種類 | アクセス経路の改善
> 医薬品・医療への公平なアクセスを促進する | 100,000 | National | Sometimes | 115032740364 |
| For example, patient narratives can be disseminated through media channels to communicate patient needs around medicine accessibility. | がん
> がん：ほとんどの種類 | アクセス経路の改善
> 医薬品・医療への公平なアクセスを促進する | 100,000 | National | Rarely | 115037193619 |
| For example, once a medicine is included in centralised procurement, it becomes unavailable for purchase outside of hospital settings. | リウマチ性
> 全身性エリテマトーデス | アクセス経路の改善
> 医薬品・医療への公平なアクセスを促進する | 100,000 | National | Sometimes | 115046738886 |
| Policy advocacy and healthcare access support constitute the core areas of business. | 肝臓
> 肝炎 | アクセス経路の改善
> 医薬品・医療への公平なアクセスを促進する | 100,000 | National | Regularly | 115050575369 |
| For example, once a medicine is included in centralised procurement, it becomes unavailable for purchase outside of hospital settings. | リウマチ性
> 全身性エリテマトーデス | アクセス経路の改善
> アクセスと管理における格差への対処 | 100,000 | National | Sometimes | 115046738886 |
| Patient needs and concerns should be communicated to policy-making bodies such as the National Healthcare Security Administration [国家医疗保障局 – China's national authority responsible for healthcare security and reimbursement policy]. | スキン
> 皮膚疾患：ほとんどの種類 | エビデンスに基づく患者の意見
> 患者のインサイトを活用して意思決定に役立てる | 100,000 | National | Sometimes | 115007238824 |
| With respect to newly marketed medicinal products, in our capacity as the initiating body of a patient assistance programme, we gather patient perspectives and, where a therapy demonstrably meets patients' clinical needs and no clinically equivalent alternative is available in China, we advocate for its market authorisation in the country — as we have done for medicines such as secukinumab [biologic medication used to treat autoimmune conditions like plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis] and Nefecon [corticosteroid budesonide used to treat primary Immunoglobulin A nephropathy]. | 全般的な健康状態
> 公衆衛生 | エビデンスに基づく患者の意見
> 患者のインサイトを活用して意思決定に役立てる | 100,000 | National | Sometimes | 115023378250 |
| We use questionnaires to gather insights into the patient population and share the resulting survey data at meetings with policymakers. | がん
> がん：ほとんどの種類 | エビデンスに基づく患者の意見
> 患者のインサイトを活用して意思決定に役立てる | 100,000 | National | Sometimes | 115033327817 |
| For example, patient narratives can be disseminated through media channels to communicate patient needs around medicine accessibility. | がん
> がん：ほとんどの種類 | エビデンスに基づく患者の意見
> 患者の体験談や生きた経験のナラティブを活用する | 100,000 | National | Rarely | 115037193619 |
| We conduct research — covering areas such as pricing and related matters — and relay the findings to the relevant regulatory authorities. | がん
> がん：ほとんどの種類 | エビデンスに基づく患者の意見
> 調査/研究を実施してデータを生成する | 100,000 | National | Sometimes | 115030437530 |
| We use questionnaires to gather insights into the patient population and share the resulting survey data at meetings with policymakers. | がん
> がん：ほとんどの種類 | エビデンスに基づく患者の意見
> 調査/研究を実施してデータを生成する | 100,000 | National | Sometimes | 115033327817 |
インタラクション
アクションと支援活動
8 メンション
